

TDMs No. 99023 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 07/26/2007

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

F1_M3

C Number: C99023

Lock Date: 12/22/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMSE Version: 1.8.0

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				3
Moribund Sacrifice	7	6	8	12
Natural Death	8	9	11	14
Survivors				
Natural Death	1			
Terminal Sacrifice	34	35	31	21
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Inflammation	2 [1.0]	6 [1.2]	3 [1.3]	8 [2.0]
Necrosis				5 [2.2]
Muscularis, Degeneration		3 [1.3]		
Gallbladder	(49)	(49)	(49)	(49)
Intestine Large, Cecum	(49)	(48)	(49)	(47)
Edema			1 [2.0]	
Lymphoid Tissue, Hyperplasia		2 [2.5]		
Intestine Small, Duodenum	(49)	(47)	(47)	(48)
Inflammation, Chronic Active				1 [3.0]
Necrosis				2 [2.0]
Intestine Small, Ileum	(49)	(47)	(47)	(47)
Intestine Small, Jejunum	(49)	(47)	(49)	(45)
Peyer's Patch, Hyperplasia, Lymphoid			2 [3.5]	
Liver	(50)	(50)	(50)	(50)
Abscess				1
Amyloid Deposition	1 [3.0]		1 [3.0]	
Angiectasis		1 [1.0]	2 [2.5]	
Basophilic Focus	3	7	6	2
Clear Cell Focus	15	21	21	2
Degeneration, Cystic			1 [1.0]	
Eosinophilic Focus	16	23	21	18
Fatty Change	25 [1.6]	18 [1.6]	16 [1.6]	29 [1.4]
Hematopoietic Cell Proliferation	3 [1.3]	2 [1.0]	2 [1.5]	1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Infarct		2 [4.0]		
Inflammation, Chronic Active	26 [1.0]	24 [1.1]	23 [1.0]	17 [1.0]
Mineralization			2 [1.5]	7 [1.0]
Mixed Cell Focus	13	3	6	3
Necrosis	7 [2.0]	10 [1.8]	13 [1.9]	17 [1.9]
Pigmentation, Ceroid	1 [2.0]			
Pigmentation, Hemosiderin	2 [2.0]	4 [1.3]		2 [1.0]
Tension Lipidosis	3 [1.0]	5 [1.6]	4 [1.5]	7 [1.3]
Thrombosis	1 [2.0]			
Vacuolization Cytoplasmic	3 [2.0]	3 [2.0]	4 [2.5]	23 [2.6]
Hepatocyte, Hypertrophy	1 [1.0]	2 [1.5]	16 [1.7]	38 [2.6]
Hepatocyte, Pigmentation, Hemosiderin			1 [1.0]	
Oval Cell, Hyperplasia		3 [2.3]	2 [1.5]	
Mesentery	(4)	(7)	(5)	(3)
Necrosis		1 [4.0]		
Fat, Necrosis	4 [2.0]	5 [2.0]	4 [1.8]	2 [2.0]
Pancreas	(50)	(50)	(50)	(50)
Atrophy	1 [1.0]	1 [1.0]		2 [1.5]
Cytoplasmic Alteration	1 [1.0]		1 [1.0]	2 [1.5]
Inflammation				1 [2.0]
Necrosis, Focal				1 [1.0]
Duct, Cyst				1 [4.0]
Salivary Glands	(50)	(50)	(50)	(50)
Inflammation	1 [2.0]		1 [2.0]	1 [2.0]
Stomach, Forestomach	(50)	(50)	(49)	(50)
Inflammation	10 [1.8]	9 [1.8]	13 [1.8]	23 [1.5]
Mineralization	1 [1.0]			
Necrosis	1 [1.0]	1 [2.0]	1 [1.0]	6 [1.3]
Ulcer	4 [2.3]	4 [1.8]	7 [1.4]	9 [2.1]
Epithelium, Hyperplasia	12 [2.1]	17 [1.6]	16 [2.0]	28 [1.9]
Epithelium, Metaplasia			1 [3.0]	
Stomach, Glandular	(50)	(50)	(50)	(50)
Dysplasia	1 [2.0]			
Hyperplasia	2 [2.0]	1 [1.0]	1 [2.0]	2 [1.0]
Inflammation	1 [1.0]		1 [2.0]	2 [1.0]
Metaplasia, Squamous		1 [1.0]	1 [1.0]	1 [1.0]
Necrosis			1 [1.0]	2 [1.5]
Muscularis, Hypertrophy	1 [2.0]			
Tongue	(1)	(0)	(0)	(0)
Tooth	(38)	(33)	(35)	(13)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Dysplasia	38	31	35	13
Gingiva, Inflammation	1 [2.0]			
Periodontal Tissue, Inflammation	1 [2.0]	1 [3.0]		
Pulp, Inflammation	1 [2.0]	3 [1.3]	1 [1.0]	
CARDIOVASCULAR SYSTEM				
Blood Vessel	(0)	(2)	(1)	(2)
Mineralization		1 [1.0]		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	15 [1.1]	12 [1.1]	13 [1.1]	19 [1.0]
Fibrosis		1 [2.0]		
Inflammation	2 [1.5]	1 [2.0]		
Mineralization	2 [2.0]	1 [1.0]	4 [1.5]	7 [1.6]
Necrosis		1 [2.0]		
Atrium, Thrombosis	1 [1.0]		2 [2.5]	1 [1.0]
Coronary Artery, Inflammation	3 [1.0]			
Vein, Venule, Thrombosis		1 [1.0]		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Amyloid Deposition	1 [2.0]			
Hypertrophy	7 [1.3]	4 [1.5]	10 [1.3]	
Necrosis				1 [1.0]
Thrombosis			1 [1.0]	
Subcapsular, Hyperplasia	46 [1.6]	47 [1.7]	46 [1.7]	43 [1.5]
Zona Fasciculata, Atrophy		1 [3.0]		
Zona Fasciculata, Hyperplasia		1 [1.0]	3 [1.3]	2 [1.0]
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 [1.0]	2 [1.0]		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	38 [1.2]	36 [1.3]	28 [1.3]	18 [1.1]
Infiltration Cellular, Mixed Cell			1 [2.0]	
Pituitary Gland	(49)	(49)	(50)	(49)
Pars Distalis, Hyperplasia	1 [1.0]	1 [3.0]		
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation				1 [1.0]
Mineralization	1 [1.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
C-cell, Hyperplasia	1 [3.0]		1 [1.0]	1 [1.0]
Follicle, Cyst	1 [1.0]	3 [1.0]		1 [2.0]
Follicle, Degeneration	1 [1.0]	1 [4.0]		2 [1.0]
Follicular Cell, Hyperplasia		4 [2.3]		2 [2.0]
Follicular Cell, Hypertrophy	1 [2.0]	1 [1.0]		
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Cyst	1 [1.0]		1 [3.0]	
Fibrosis	1 [1.0]			
Granuloma Sperm	1 [1.0]			
Inflammation			2 [2.0]	
Mineralization				1 [1.0]
Preputial Gland	(50)	(50)	(50)	(50)
Ectasia	4 [2.3]	5 [2.4]	4 [2.0]	3 [2.3]
Inflammation	5 [2.8]	3 [2.7]	2 [3.5]	2 [1.5]
Prostate	(50)	(50)	(50)	(50)
Atrophy			1 [2.0]	
Hyperplasia		2 [2.0]		
Inflammation	25 [1.1]	15 [1.1]	22 [1.0]	12 [1.0]
Seminal Vesicle	(50)	(50)	(50)	(50)
Atrophy			1 [3.0]	
Inflammation			1 [3.0]	
Testes	(50)	(50)	(50)	(50)
Germinal Epithelium, Degeneration	5 [1.2]	2 [2.0]	5 [2.2]	18 [1.3]
Germinal Epithelium, Mineralization			2 [1.0]	2 [1.5]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Atrophy	1 [2.0]		1 [2.0]	18 [2.3]
Myelofibrosis	1 [1.0]		1 [1.0]	1 [1.0]
Necrosis, Focal		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Pigmentation		1 [2.0]	1 [2.0]	1 [2.0]
Myeloid Cell, Hyperplasia	1 [2.0]	3 [2.0]	3 [1.7]	1 [4.0]
Lymph Node	(2)	(0)	(5)	(1)
Inguinal, Atrophy			1 [3.0]	
Inguinal, Infiltration Cellular, Histiocyte			1 [2.0]	
Mediastinal, Inflammation, Granulomatous			1 [2.0]	
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Atrophy	3 [3.0]	6 [1.2]	9 [1.6]	23 [2.1]
Hyperplasia, Lymphoid		3 [1.7]	2 [3.0]	
Infiltration Cellular, Plasma Cell	1 [3.0]	3 [2.0]	1 [1.0]	
Lymph Node, Mesenteric	(49)	(50)	(47)	(44)
Amyloid Deposition	1 [1.0]			
Atrophy	12 [1.9]	12 [1.7]	13 [2.3]	28 [2.6]
Hyperplasia, Lymphoid		2 [1.5]	1 [2.0]	
Infiltration Cellular, Plasma Cell		1 [2.0]		
Inflammation	1 [2.0]			
Inflammation, Granulomatous			1 [4.0]	
Pigmentation, Hemosiderin	1 [2.0]			
Spleen	(49)	(50)	(48)	(49)
Amyloid Deposition	1 [2.0]		1 [1.0]	
Hematopoietic Cell Proliferation	33 [1.8]	43 [1.9]	41 [2.2]	10 [1.9]
Hyperplasia, Lymphoid	1 [2.0]		1 [3.0]	2 [2.0]
Infiltration Cellular, Histiocyte			1 [2.0]	1 [2.0]
Pigmentation, Hemosiderin	1 [1.0]	1 [1.0]		2 [1.5]
Lymphoid Follicle, Atrophy	7 [2.1]	5 [2.2]	10 [2.9]	31 [3.3]
Lymphoid Follicle, Hyperplasia			1 [2.0]	
Thymus	(47)	(47)	(48)	(47)
Amyloid Deposition	1 [1.0]			
Atrophy	45 [2.4]	40 [2.3]	44 [2.6]	41 [3.0]
Hyperplasia, Lymphoid				1 [2.0]
Infiltration Cellular, Plasma Cell				1 [2.0]
Necrosis				1 [3.0]
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Infiltration Cellular, Mast Cell, Focal		1 [3.0]		
Inflammation	1 [2.0]		2 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Ulcer	1 [3.0]	2 [3.5]	3 [4.0]	
Hair Follicle, Inflammation	1 [2.0]			
Sebaceous Gland, Hyperplasia				1 [3.0]
Subcutaneous Tissue, Edema			1 [2.0]	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy				1 [4.0]
Osteoporosis		1 [3.0]		
Joint, Arthrosis	1 [4.0]			
Skeletal Muscle	(0)	(2)	(1)	(1)
Inflammation		1 [2.0]		1 [2.0]
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Vein, Infiltration Cellular, Lymphocyte			1 [1.0]	
Peripheral Nerve	(0)	(0)	(1)	(0)
Infiltration Cellular, Lymphocyte			1 [2.0]	
Spinal Cord	(0)	(0)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Abscess				1
Foreign Body				1
Hematopoietic Cell Proliferation			1 [2.0]	
Inflammation, Suppurative			1 [2.0]	1 [1.0]
Inflammation, Chronic Active	2 [1.5]	1 [1.0]	1 [1.0]	3 [1.3]
Thrombosis			1 [1.0]	1 [1.0]
Alveolar Epithelium, Hyperplasia	4 [1.5]	8 [2.0]	5 [2.4]	5 [1.8]
Alveolus, Infiltration Cellular, Histiocyte	4 [2.5]	9 [1.8]	1 [2.0]	3 [2.0]
Arteriole, Degeneration		1 [1.0]		
Bronchiole, Hyperplasia	1 [1.0]	2 [2.0]		1 [2.0]
Glands, Inflammation		2 [1.5]	1 [2.0]	
Nose	(50)	(50)	(50)	(50)
Inflammation	3 [2.3]	2 [2.0]	2 [1.5]	3 [1.7]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Polyp, Inflammatory Glands, Dilatation	6 [2.3]	3 [1.7]	1 [1.0]	
Olfactory Epithelium, Degeneration	5 [1.2]	5 [1.2]	7 [1.1]	6 [1.2]
Olfactory Epithelium, Metaplasia, Respiratory	7 [2.3]	2 [2.0]	1 [2.0]	
Respiratory Epithelium, Hyperplasia	1 [1.0]	1 [2.0]		
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Fibrosis			1 [3.0]	
Thrombosis				1 [3.0]
Cornea, Hyperplasia, Squamous		2 [2.0]		
Cornea, Inflammation		2 [2.0]		1 [1.0]
Lens, Cataract		2 [3.0]		
Optic Nerve, Fibrosis	1 [2.0]	1 [2.0]		
Retina, Degeneration		2 [1.5]		
Harderian Gland	(50)	(50)	(50)	(50)
Fibrosis	1 [2.0]	1 [3.0]		
Hyperplasia	1 [2.0]	3 [2.7]	2 [1.0]	2 [2.5]
Inflammation				1 [4.0]
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet			3 [1.7]	
Infarct	6 [2.2]	6 [1.7]	7 [1.6]	1 [3.0]
Mineralization	31 [1.0]	31 [1.0]	29 [1.0]	12 [1.3]
Nephropathy	44 [1.4]	44 [1.6]	43 [1.3]	27 [1.3]
Cortex, Cyst	6 [1.0]	6 [1.3]	4 [1.0]	3 [1.7]
Cortex, Inflammation	1 [4.0]	2 [3.0]		
Cortex, Metaplasia, Osseous	1 [1.0]			
Papilla, Inflammation	1 [3.0]	2 [2.5]		1 [2.0]
Papilla, Necrosis	1 [4.0]	1 [1.0]	1 [2.0]	
Pelvis, Dilatation			1 [3.0]	
Pelvis, Inflammation	1 [2.0]		2 [2.0]	
Renal Tubule, Hyperplasia	14 [1.3]	16 [1.1]	14 [1.1]	6 [1.2]
Renal Tubule, Necrosis			3 [1.3]	18 [2.3]
Renal Tubule, Pigmentation,	1 [2.0]	2 [4.0]	1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Hemosiderin Renal Tubule, Vacuolization Cytoplasmic Urinary Bladder Inflammation	39 [1.2] (50)	41 [1.3] (50)	20 [1.1] (49) 1 [3.0]	(49)

*** END OF MALE ***

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1	1	
Moribund Sacrifice	4	5	6	5
Natural Death	7	10	8	28
Survivors				
Terminal Sacrifice	39	34	35	17
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Inflammation	2 [1.0]	1 [2.0]	4 [2.5]	
Necrosis			2 [2.5]	
Muscularis, Degeneration	1 [1.0]		1 [1.0]	
Gallbladder	(47)	(50)	(50)	(49)
Intestine Large, Cecum	(49)	(50)	(50)	(47)
Edema			1 [3.0]	
Inflammation			1 [2.0]	
Epithelium, Metaplasia			1 [2.0]	
Intestine Large, Colon	(50)	(50)	(50)	(47)
Parasite Metazoan				1 [1.0]
Epithelium, Inflammation			1 [1.0]	
Intestine Large, Rectum	(50)	(49)	(50)	(49)
Inflammation			1 [1.0]	
Necrosis			1 [2.0]	
Intestine Small, Jejunum	(50)	(48)	(49)	(40)
Peyer's Patch, Hyperplasia, Lymphoid			3 [2.3]	
Serosa, Fibrosis		1 [2.0]		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 [2.0]	1 [3.0]	2 [2.0]	
Basophilic Focus	2	1	4	1
Clear Cell Focus		1	1	
Cytoplasmic Alteration				1 [1.0]
Eosinophilic Focus	4	5	6	9
Fatty Change	29 [1.6]	35 [1.4]	16 [1.3]	15 [1.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Hematopoietic Cell Proliferation	6 [1.2]	1 [2.0]	1 [2.0]	1 [1.0]
Infiltration Cellular, Lymphocyte		4 [2.3]	1 [1.0]	
Inflammation, Suppurative				1 [2.0]
Inflammation, Chronic Active	43 [1.0]	35 [1.1]	34 [1.0]	14 [1.1]
Mineralization				1 [1.0]
Mixed Cell Focus	1	4	6	1
Necrosis	3 [1.3]	2 [1.5]	3 [1.7]	7 [1.7]
Pigmentation, Hemosiderin	2 [1.0]		2 [1.0]	
Regeneration		1 [3.0]		
Tension Lipidosis	12 [1.0]	3 [1.0]	10 [1.3]	4 [1.8]
Vacuolization Cytoplasmic	6 [2.5]	11 [1.7]	8 [3.6]	30 [2.8]
Bile Duct, Crystals			1 [2.0]	
Bile Duct, Hyperplasia		1 [2.0]	1 [2.0]	
Hepatocyte, Hypertrophy			6 [1.5]	40 [2.0]
Oval Cell, Hyperplasia	1 [4.0]		1 [3.0]	
Mesentery	(15)	(18)	(3)	(0)
Fat, Necrosis	14 [1.9]	15 [2.6]	1 [1.0]	
Pancreas	(50)	(49)	(50)	(48)
Atrophy	2 [4.0]	1 [3.0]	3 [3.3]	1 [4.0]
Basophilic Focus			1 [1.0]	
Inflammation, Granulomatous			1 [2.0]	
Mineralization				1 [2.0]
Necrosis				1 [2.0]
Acinus, Cytoplasmic Alteration, Focal		1 [1.0]		
Duct, Cytoplasmic Alteration			1 [2.0]	
Salivary Glands	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte		1 [2.0]		
Stomach, Forestomach	(50)	(49)	(50)	(47)
Inflammation	2 [1.5]	5 [1.4]	8 [1.4]	19 [1.5]
Mineralization				1 [1.0]
Necrosis			4 [1.3]	6 [1.5]
Ulcer	3 [1.7]	2 [2.0]	3 [2.0]	8 [1.8]
Epithelium, Hyperplasia	7 [2.0]	10 [1.5]	17 [1.8]	24 [1.5]
Stomach, Glandular	(50)	(50)	(50)	(49)
Cytoplasmic Alteration, Focal	1 [1.0]			
Inflammation	1 [1.0]			2 [1.0]
Mineralization				1 [2.0]
Necrosis				2 [1.0]
Tooth	(1)	(3)	(4)	(0)
Dysplasia	1	3	4	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
CARDIOVASCULAR SYSTEM				
Blood Vessel	(2)	(2)	(2)	(1)
Inflammation, Chronic Active	1 [2.0]			
Mineralization	1 [3.0]	2 [3.0]		
Aorta, Inflammation				1 [2.0]
Carotid Artery, Intima, Hyperplasia			1 [4.0]	
Media, Degeneration	1 [2.0]			
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	7 [1.0]	1 [1.0]	4 [1.0]	4 [1.0]
Degeneration		1 [2.0]		
Fibrosis			1 [2.0]	1 [3.0]
Inflammation	1 [3.0]	2 [4.0]		
Mineralization	1 [1.0]	2 [1.5]	2 [1.0]	5 [1.2]
Pigmentation, Hemosiderin		1 [1.0]		
Atrium, Thrombosis			1 [1.0]	
Coronary Artery, Inflammation	1 [2.0]		1 [2.0]	
Epicardium, Inflammation		1 [3.0]		
Valve, Thrombosis	2 [3.0]	2 [4.0]		1 [4.0]
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hypertrophy			3 [1.0]	
Capsule, Fibrosis		1 [2.0]		
Capsule, Infiltration Cellular, Lymphocyte		1 [2.0]		
Subcapsular, Hyperplasia	50 [2.8]	50 [2.7]	49 [2.9]	50 [2.4]
Zona Fasciculata, Hyperplasia	1 [2.0]	2 [1.0]		
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 [2.0]	2 [3.0]		
Parathyroid Gland	(47)	(34)	(43)	(44)
Cyst		1 [2.0]		
Hyperplasia	1 [2.0]			
Infiltration Cellular, Lymphocyte	1 [1.0]			
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Hyperplasia	1 [2.0]	2 [2.5]	5 [1.6]	2 [2.0]
Pars Intermedia, Hyperplasia			1 [2.0]	
Pars Nervosa, Inflammation		1 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation	2 [1.0]	2 [1.0]		1 [1.0]
C-cell, Hyperplasia			1 [1.0]	
Follicle, Cyst	1 [1.0]	1 [2.0]	3 [1.7]	3 [1.7]
Follicle, Degeneration	1 [1.0]			
Follicular Cell, Hyperplasia	2 [1.5]	1 [1.0]	3 [1.0]	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(49)	(48)	(50)	(49)
Ovary	(50)	(50)	(49)	(49)
Amyloid Deposition			1 [2.0]	
Angiectasis	1 [3.0]	2 [2.5]	1 [2.0]	2 [1.5]
Atrophy	43 [2.6]	44 [3.2]	45 [3.3]	43 [3.0]
Hyperplasia, Tubular			1 [2.0]	2 [1.5]
Inflammation			1 [1.0]	
Inflammation, Granulomatous		1 [1.0]		
Thrombosis	1 [4.0]			1 [4.0]
Corpus Luteum, Cyst		2 [1.0]	1 [1.0]	
Follicle, Cyst	5 [2.2]	4 [1.5]	4 [2.0]	
Follicle, Cyst, Multiple			1 [3.0]	
Germinal Epithelium, Cyst	1 [2.0]	2 [1.5]	1 [3.0]	1 [4.0]
Germinal Epithelium, Cyst, Multiple			1 [2.0]	
Periovarian Tissue, Cyst		1 [2.0]	1 [1.0]	
Rete Ovarii, Cyst		1 [4.0]		2 [3.5]
Oviduct	(0)	(0)	(1)	(0)
Uterus	(50)	(50)	(50)	(50)
Angiectasis		1 [2.0]	1 [2.0]	2 [1.5]
Thrombosis			1 [2.0]	
Endometrium, Hyperplasia	43 [2.9]	33 [2.3]	28 [2.3]	23 [1.7]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(49)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Atrophy	1 [2.0]		7 [2.6]	29 [2.6]
Myelofibrosis	16 [1.4]	9 [1.3]	4 [1.5]	3 [1.3]
Necrosis		1 [2.0]		
Myeloid Cell, Hyperplasia	2 [1.5]	1 [3.0]	1 [2.0]	
Lymph Node	(7)	(8)	(7)	(0)
Bronchial, Hyperplasia, Lymphoid	1 [3.0]		1 [2.0]	
Inguinal, Infiltration Cellular, Plasma Cell	1 [1.0]			
Renal, Amyloid Deposition	1 [2.0]			
Renal, Ectasia	1 [4.0]			
Renal, Infiltration Cellular, Plasma Cell	1 [1.0]			
Lymph Node, Mandibular	(50)	(50)	(49)	(49)
Amyloid Deposition	1 [1.0]			
Atrophy	4 [1.5]	8 [1.3]	11 [1.5]	22 [1.5]
Hyperplasia, Lymphoid	3 [3.0]	2 [2.5]	1 [2.0]	1 [4.0]
Infiltration Cellular, Plasma Cell	1 [1.0]			
Lymph Node, Mesenteric	(47)	(48)	(44)	(39)
Atrophy	9 [1.8]	7 [2.0]	5 [2.0]	25 [2.5]
Hyperplasia, Lymphoid	1 [1.0]			
Spleen	(49)	(50)	(50)	(50)
Amyloid Deposition	1 [1.0]			
Hematopoietic Cell Proliferation	39 [1.7]	39 [1.8]	16 [2.3]	11 [1.6]
Hyperplasia, Lymphoid	6 [2.3]	4 [2.5]	4 [2.5]	1 [2.0]
Infiltration Cellular, Plasma Cell	1 [1.0]	1 [2.0]		
Pigmentation, Hemosiderin	9 [1.1]	16 [1.3]	11 [1.3]	14 [1.3]
Lymphoid Follicle, Atrophy	4 [2.0]	11 [2.6]	11 [2.9]	32 [3.6]
Lymphoid Follicle, Hyperplasia			1 [2.0]	
Thymus	(49)	(48)	(47)	(48)
Amyloid Deposition	1 [2.0]			
Atrophy	22 [2.0]	14 [3.1]	19 [2.9]	38 [3.3]
Hyperplasia, Atypical			1 [2.0]	
Infiltration Cellular, Plasma Cell	1 [2.0]	1 [3.0]		
Inflammation		1 [2.0]		
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia			1 [2.0]	
Duct, Dilatation			1 [2.0]	
Skin	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Ulcer			1 [4.0]	
Hair Follicle, Inflammation, Diffuse		1 [2.0]		
Sebaceous Gland, Hyperplasia, Focal			1 [3.0]	
Subcutaneous Tissue, Fibrosis	1 [2.0]	1 [3.0]		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Joint, Degeneration	1 [2.0]			
Tibia, Osteosclerosis	1 [2.0]			
Skeletal Muscle	(0)	(3)	(0)	(0)
Inflammation		1 [2.0]		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Cerebellum, Necrosis			1 [2.0]	
Cerebrum, Necrosis			1 [3.0]	
Hippocampus, Necrosis			1 [3.0]	
Medulla, Demyelination, Focal		1 [2.0]		
Vein, Infiltration Cellular, Lymphocyte	1 [2.0]		1 [2.0]	
Peripheral Nerve	(0)	(1)	(0)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid				1 [2.0]
Inflammation, Suppurative		1 [3.0]		
Inflammation, Chronic Active	4 [1.3]	1 [1.0]	1 [2.0]	3 [1.0]
Pigmentation, Hemosiderin			1 [1.0]	
Alveolar Epithelium, Hyperplasia	2 [2.5]	3 [1.7]	2 [2.5]	5 [2.2]
Alveolus, Infiltration Cellular, Histiocyte	5 [1.4]		3 [2.0]	1 [1.0]
Bronchiole, Hyperplasia	1 [2.0]	1 [2.0]		1 [2.0]
Serosa, Fibrosis, Focal	1 [3.0]			
Serosa, Inflammation, Suppurative				1 [2.0]
Nose	(50)	(50)	(50)	(50)
Olfactory Epithelium, Degeneration	2 [1.5]	5 [1.0]	5 [1.0]	12 [1.1]
Olfactory Epithelium, Metaplasia,		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Respiratory Respiratory Epithelium, Hyperplasia Trachea Epithelium, Glands, Cytoplasmic Alteration	1 [2.0] (50)	(50)	(50) 1 [2.0]	(50)
SPECIAL SENSES SYSTEM				
Ear Necrosis	(0)	(0)	(1) 1 [3.0]	(0)
Eye Atrophy Synechia	(50) 1 [4.0]	(50)	(50) 1 [2.0]	(49)
Cornea, Inflammation Lens, Cataract Retina, Retinal Detachment	1 [3.0]	1 [2.0]	1 [1.0] 2 [1.0] 1 [2.0]	
Harderian Gland Fibrosis Hyperplasia	(50) 1 [3.0] 1 [1.0]	(50) 2 [3.0]	(50) 1 [1.0]	(49)
URINARY SYSTEM				
Kidney Accumulation, Hyaline Droplet Amyloid Deposition Infarct Infiltration Cellular, Lymphocyte Mineralization Nephropathy Cortex, Cyst Cortex, Metaplasia, Osseous Glomerulus, Amyloid Deposition Papilla, Inflammation Papilla, Necrosis Pelvis, Dilatation Renal Tubule, Hyperplasia Renal Tubule, Necrosis	(50) 4 [1.8] 1 [3.0] 10 [1.5] 20 [1.1] 1 [3.0] 1 [3.0] 1 [2.0] 2 [2.0]	(50) 1 [4.0] 4 [1.0] 3 [2.0] 13 [1.0] 21 [1.1] 2 [1.5] 2 [2.0] 1 [1.0] 2 [1.0]	(50) 1 [4.0] 3 [2.7] 4 [2.0] 8 [1.4] 16 [1.4] 1 [2.0] 1 [3.0] 1 [1.0] 2 [2.5]	(50) 1 [3.0] 1 [1.0] 8 [1.3] 16 [1.0] 2 [1.5] 17 [2.4]
Ureter Urinary Bladder	(0) (50)	(0) (50)	(1) (50)	(0) (49)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Reqsted: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Infiltration Cellular, Lymphocyte Arteriole, Inflammation	1 [2.0]	2 [2.5] 1 [2.0]		1 [3.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)